ArticleNature cancer2024
Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
16.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 72 citations in OpenAlex.
- Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.Nature communications · 2025Trial
- Cancer-associated fibroblasts in therapeutic resistance of hepatocellular carcinoma: evidence, mechanisms, and translational implications.Medical oncology (Northwood, London, England) · 2026Review
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- Review
- miR-486-5p suppresses autophagy in hepatocellular carcinoma via activation of the AKT/mTOR signalling pathway.Molecular biomedicine · 2026Article
- Review
- An Integrated Spatial Multi-Omics Workflow for Sequential RNA and Protein Profiling in FFPE Tumor Tissue.Cancer research communications · 2026Article
- COLEC12high tumor-associated macrophages: A novel paracrine axis driving lenvatinib resistance in hepatocellular carcinoma: Editorial on "COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling".Clinical and molecular hepatology · 2026Article
- Modulation of the tumor microenvironment by incretins and glucagon: Metabolic and immune mechanisms (Review).Experimental and therapeutic medicine · 2026Review
- Spatial transcriptomics in cancer research: insights into tumorigenesis, diagnosis and therapeutics.Cell death discovery · 2026Review
- Review
- The versatile interplay between steatotic liver disease and liver cancer.Nature reviews. Cancer · 2026Review
- Multi-omics insights for deciphering prognosis-related T cell subsets in hepatocellular carcinoma.Clinical and translational medicine · 2026Article
- Spatial characterization of skin lesions in discoid and systemic lupus erythematosus.Nature communications · 2026Article
- Charting spatial ligand-target activity using Renoir.Nature communications · 2026Article
- Spatiotemporal Transcriptomics Characterizes Immune Microenvironment During Mouse Liver Aging.Aging cell · 2026Article
- Reinvigorating COTL1Nature cell biology · 2026Article
- Decoding the CAF-TAM axis: multi-omics dissection and therapeutic targeting of stromal-immune crosstalk in the tumor microenvironment.Cell death & disease · 2026Review
- Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy.Clinical and molecular hepatology · 2026Review
- Targeting Tumor-Associated Macrophages and Cancer-Associated Fibroblasts to Overcome Therapeutic Resistance in Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 11 institutions in 4 countries.
Ziyi LiShanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0003-0947-9137
Rhea Pai *Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, Perth, Western Australia, Australia.
Saurabh Gupta *Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, Perth, Western Australia, Australia.
Jennifer Currenti *Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, Perth, Western Australia, Australia.
Wei Guo *Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Anna Di BartolomeoStorr Liver Centre, The Westmead Institute for Medical Research and Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
Hao FengDepartment of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zijie ZhangDepartment of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID http://orcid.org/0000-0002-2513-3091
Zhizhen LiDepartment of Biliary Tract Surgery I, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Longqi LiuBGI-Shenzhen, Beishan Industrial Zone, Shenzhen, P. R. China.ORCID http://orcid.org/0000-0002-5828-5542
Abhishek SinghHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, Perth, Western Australia, Australia.
Yinqi BaiBGI-Shenzhen, Beishan Industrial Zone, Shenzhen, P. R. China.
Bicheng YangBGI-Australia, Herston, Queensland, Australia.
Archita MishraSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore.
Katharine YangSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore.
Liang QiaoStorr Liver Centre, The Westmead Institute for Medical Research and Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
Michael WallaceDepartment of Hepatology and Western Australian Liver Transplant Service, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Yujia YinDepartment of Obstetrics and Gynecology, Xinhua Hospital Affiliated to Shanghai Jiaotong University Medicine School, Shanghai, China.
Qiang XiaDepartment of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jerry Kok Yen ChanDepartment of Reproductive Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Jacob GeorgeStorr Liver Centre, The Westmead Institute for Medical Research and Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.ORCID http://orcid.org/0000-0002-8421-5476
Pierce Kah-Hoe ChowDepartment of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore. pierce.chow@duke-nus.edu.sg.ORCID http://orcid.org/0000-0003-0584-2584
Florent GinhouxShanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. florent_ginhoux@immunol.a-star.edu.sg.ORCID http://orcid.org/0000-0002-2857-7755
Ankur SharmaHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, Perth, Western Australia, Australia. ankur.sharma@perkins.org.au.ORCID http://orcid.org/0000-0002-6862-136X
Curtin University · AUShanghai Jiao Tong University · CNAgency for Science, Technology and Research · SGThe University of Sydney · AUBGI Group (China) · CNSecond Military Medical University · CNHarry Perkins Institute of Medical Research · AUNational University of Singapore · SGSingapore General Hospital · SGThe University of Western Australia · AUXinHua Hospital · CN
Funding
Department of Health | National Health and Medical Research Council (NHMRC) 2021/GNT2010795Department of Health | National Health and Medical Research Council (NHMRC) 2022/MRF2016215National Research FoundationSingapore (National Research Foundation-Prime Minister's office, Republic of Singapore) NRF2016NRF-NRFI001-02
Abstract
Onco-fetal reprogramming of the tumor ecosystem induces fetal developmental signatures in the tumor microenvironment, leading to immunosuppressive features. Here, we employed single-cell RNA sequencing, spatial transcriptomics and bulk RNA sequencing to delineate specific cell subsets involved in hepatocellular carcinoma (HCC) relapse and response to immunotherapy. We identified POSTN
Indexed as
Carcinoma, HepatocellularFolate Receptor 2Liver NeoplasmsCell MovementChronic DiseaseEcosystemEndothelial CellsHumansImmunotherapyRecurrenceTumor MicroenvironmentFolate Receptor 2FOLR2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.